Welcome, Guest
Username: Password: Remember me
General
  • Page:
  • 1

TOPIC: CYTX To Expand Scleroderma Focus

CYTX To Expand Scleroderma Focus 10 Jan 2017 08:39 #8468

  • rodney.strongg
  • rodney.strongg's Avatar Topic Author
  • Away
  • Platinum Boarder
  • Platinum Boarder
  • Posts: 1275
  • Thank you received: 18
CYTX announced its intention to broaden its investigation of the ECCS-50 formulation to include secondary Raynaud's phenomenon, a problem that affects over one million patients worldwide. "Habeo Cell Therapy" (formerly ECCS-50) is the new brand name.

See press release for further information.
.

Please Log in or Create an account to join the conversation.

CYTX To Expand Scleroderma Focus 10 Jan 2017 09:14 #8469

  • fas
  • fas's Avatar
  • Offline
  • Moderator
  • Moderator
  • May the fat be with you
  • Posts: 3295
  • Thank you received: 1110

rodney.strongg wrote: CYTX announced its intention to broaden its investigation of the ECCS-50 formulation to include secondary Raynaud's phenomenon, a problem that affects over one million patients worldwide. "Habeo Cell Therapy" (formerly ECCS-50) is the new brand name.

See press release for further information.
.


That press release is so important that one should read this a few times...:grin:

Jan 10, 2017
SAN DIEGO, Jan. 10, 2017 (GLOBE NEWSWIRE) -- Cytori Therapeutics, Inc. (NASDAQ:CYTX), as part of its corporate update at the Biotech Showcase, announced its intention to broaden its investigation of the ECCS-50 formulation of Cytori Cell Therapy® to include secondary Raynaud’s phenomenon (RP) beyond scleroderma, a problem that affects over one million patients worldwide. Habeo Cell Therapy (formerly ECCS-50) is the new brand name of Cytori Therapeutics’ hand therapy franchise.
“Pilot trial data suggest that our ECCS-50 cellular therapeutic may help to address Secondary RP symptoms and other autoimmune and inflammatory conditions of the hand,” said Dr. Marc H. Hedrick, Cytori President and Chief Executive Officer. “Our plan is to leverage published and ongoing preclinical and clinical data to expand our investigation of ECCS-50 to a much larger patient population with secondary RP under the new Habeo brand name.”
In addition to its substantial contribution to the disease burden of scleroderma, RP is a source of significant morbidity in several more common autoimmune and inflammatory conditions including rheumatoid arthritis, systemic lupus erythematosus (lupus), and Sjogren’s syndrome. The worldwide prevalence of moderate-to-severe RP in these three diseases alone exceeds one million patients, providing an estimated peak annual revenue potential of $1.6 billion.
“Habeo, pronounced ‘habēō,’ means ‘to hold’ in Latin,” explained John Harris, Vice President & General Manager, Cell Therapy. “The name embodies the promise that we believe Cytori Cell Therapy holds for patients with a number of disorders that affect the hand by potentially improving function, reducing pain, and restoring activities of daily living.”
Broadening of clinical interest to secondary RP in other autoimmune and inflammatory diseases is based in large part on 36-month follow-up data from the investigator-initiated, 12-patient, open-label SCLERADEC I trial, which reported a 90 percent reduction in the Raynaud’s Condition Score, a clinically validated scale for determining the degree of difficulty experienced by patients with RP. Earlier limited published data has also reported improvement in vascular architecture, hand color, and other direct and indirect indicators of vascular function. Cytori’s internal preclinical data provide further support for a potential role of Habeo Cell Therapy in the stabilization of the vascular endothelium, an important contributor to the vascular dysfunction found in patients with RP.
RP is a key secondary endpoint in the STAR clinical trial, Cytori’s randomized, double-blind, placebo-controlled Phase 3 clinical trial in patients with scleroderma. Cytori anticipates unblinding of the trial data in mid-2017. The combination of the anticipated US-based STAR data with clinical data from the completed SCLERADEC I pilot trial, anticipated clinical data from the ongoing SCLERADEC II trial in Europe, the accumulated preclinical data, patient advocacy awareness, extensive market analysis, and Cytori’s intellectual property position provide compelling support for continued research, development and commercial planning of Habeo Cell Therapy in Secondary RP.

Please Log in or Create an account to join the conversation.

Board moderator and Site-owner. I still regret the day I started analysing the prospects of MacroPore (now Cytori) back in 2004- a left-over from the tech-bubble at that time from the century change in my portfolio- and became addicted to Cytori´s fat cell technology. :cry:

CYTX To Expand Scleroderma Focus 10 Jan 2017 09:33 #8470

  • fas
  • fas's Avatar
  • Offline
  • Moderator
  • Moderator
  • May the fat be with you
  • Posts: 3295
  • Thank you received: 1110
Dear Raccoon Lodge members-

I must say- this announcement kind of soothes my over-extended highly strained nerves in respect of the future of Cytori. This makes all sense of the world and is just a beginning. I think the opportunity described to a third party potential partner will be highly compelling and attractive.

This is a nice starting point for the paradigm change that I always saw in CCT- major thing to know is also- after developing the hand opportunity- that conventional medicine is totally off-base with its cholesterol and arterial clogging theories.
In reality most ischemic issues surrounding the vascular system (resulting in stroke, MY and PAD etc etc) are caused by inflammation resulting in endothelial dysfunction of the arteries and the organs served by the vascular system. CCT will do wonders there in the right dose and is also the reason of the "miracle stories of Mitsuo from 2009 who experimented with CCT on several patients suffering from (basically) endothelial dysfunction". What he is doing now- basically chelation therapy- combined with CCT will help a lot of patients going forward. :grin:

Our days will come.

Please Log in or Create an account to join the conversation.

Board moderator and Site-owner. I still regret the day I started analysing the prospects of MacroPore (now Cytori) back in 2004- a left-over from the tech-bubble at that time from the century change in my portfolio- and became addicted to Cytori´s fat cell technology. :cry:

CYTX To Expand Scleroderma Focus 10 Jan 2017 10:08 #8471

  • rodney.strongg
  • rodney.strongg's Avatar Topic Author
  • Away
  • Platinum Boarder
  • Platinum Boarder
  • Posts: 1275
  • Thank you received: 18
Fas, could be further info when Hedrick presents today at 4:00 pm PT at the Biotech Showcase - a live audio webcast will be available under the IR section of Cytx's website at www.cytori.com .

Please Log in or Create an account to join the conversation.

CYTX To Expand Scleroderma Focus 10 Jan 2017 10:49 #8472

  • franshei
  • franshei's Avatar
  • Offline
  • Platinum Boarder
  • Platinum Boarder
  • Posts: 788
  • Thank you received: 102
Rodney Strong

This stock has been manipulated - just look at the price action today.

The negative power is strong.

Some x-stock holders (a few of them) have been attacking this stock on this very board. They have posted very long messages - probably they are paid for the length of the messages.

Please Log in or Create an account to join the conversation.

CYTX To Expand Scleroderma Focus 10 Jan 2017 11:01 #8473

  • rodney.strongg
  • rodney.strongg's Avatar Topic Author
  • Away
  • Platinum Boarder
  • Platinum Boarder
  • Posts: 1275
  • Thank you received: 18
Franshei, it has been manipulated for a long time - however, when we get that cash partnership (and Habeo just reeks of that happening before too long), the buying strength will overwhelm the "game players" and today's price will be a distant memory imo.

Please Log in or Create an account to join the conversation.

CYTX To Expand Scleroderma Focus 10 Jan 2017 17:17 #8474

  • waddlingwillbologni
  • waddlingwillbologni's Avatar
  • Visitor
  • Visitor
The obvious move:

1) will lighten the blow with a Scleroderma failure, providing a fallback and thread of hope to potentially keep doors open, to potentially keep luring investors, etc. (you all should know how this goes by now ...);

2) will broaden the revenue potential for possible partnerships based on a successful Scleroderma trial, partnerships they aren't solidifying as things are.

A successful trial, or another failure -- this, is the question ...

Please Log in or Create an account to join the conversation.

CYTX To Expand Scleroderma Focus 13 Jan 2017 09:25 #8496

  • franshei
  • franshei's Avatar
  • Offline
  • Platinum Boarder
  • Platinum Boarder
  • Posts: 788
  • Thank you received: 102
Fas,

The scleroderma indication by itself is narrow and Harris has expressed at times at such a market in Japan is small. Adding Raynaud's phenomenon as a post approval indication (phase 4) is a good marketing strategy.

Harris knows his Asian market well and CYTX is profitable in Japan (Hedrick's presentation).

Harris' Asian strategy is very careful. I think with increasing tension between China and its neighbors as well as the US, Harris is avoiding China presently. Harris' territories are all well protected, even if there is a conflict in South China Sea.(Kool may not do well, as it is now a BOYaLIFE company, a Chinese government funded entity.) Japan is a very important US friend in Asia.

Please Log in or Create an account to join the conversation.

CYTX To Expand Scleroderma Focus 13 Jan 2017 10:50 #8499

  • fas
  • fas's Avatar
  • Offline
  • Moderator
  • Moderator
  • May the fat be with you
  • Posts: 3295
  • Thank you received: 1110

franshei wrote: Fas,

The scleroderma indication by itself is narrow and Harris has expressed at times at such a market in Japan is small. Adding Raynaud's phenomenon as a post approval indication (phase 4) is a good marketing strategy.

Harris knows his Asian market well and CYTX is profitable in Japan (Hedrick's presentation).

Harris' Asian strategy is very careful. I think with increasing tension between China and its neighbors as well as the US, Harris is avoiding China presently. Harris' territories are all well protected, even if there is a conflict in South China Sea.(Kool may not do well, as it is now a BOYaLIFE company, a Chinese government funded entity.) Japan is a very important US friend in Asia.


Franshei-

Raynaud´s being the top secondary endpoint in STAR and in itself a less complicated disorder compared to Scleroderma, should not be a big issue from a technology perspective- blood flow works and the cells stick around nicely in the hand apparently.


Raynaud's disease is a vascular disorder that causes intermittent interruption of blood flow to the extremities. The affected body part may turn white or blue and feel cold and numb until circulation improves.

Whatever the politics in Asia and the strategy of Harris/Hedrick, for me - key being that the range of treatable patient population increases tremendously- GLOBALLY that is.
If you read about the present standard of care- being the usual cardiac/hypertension medication, with primarily calcium channel blocker (like Amlodipine) and also ACE inhibitors, Viagra and even Statins (of all :puke: ), it is clear that ADRCs can do very well here and if we survive 1-2 years, Cytori will become a monster Company, since there is plenty coming our way. :grin:

Please Log in or Create an account to join the conversation.

Board moderator and Site-owner. I still regret the day I started analysing the prospects of MacroPore (now Cytori) back in 2004- a left-over from the tech-bubble at that time from the century change in my portfolio- and became addicted to Cytori´s fat cell technology. :cry:

CYTX To Expand Scleroderma Focus 13 Jan 2017 13:37 #8502

  • franshei
  • franshei's Avatar
  • Offline
  • Platinum Boarder
  • Platinum Boarder
  • Posts: 788
  • Thank you received: 102
Fas, In Hedrick's JPM presentation, he indicates that scleroderma efficacy is evident as early as 2 weeks post treatment (? !).

I think CYTX insiders/medical staff may have some early signs re direction of the STAR trial. I think Jason has asked an important question during the 3rd Q CC: re any changes needed for the study in mid stream. When Hedrick indicates no, Jason's spontaneous reply is: this is what I want to hear.

Please Log in or Create an account to join the conversation.

  • Page:
  • 1
Time to create page: 0.143 seconds

Copyright Information

Copyright Fas Kuiters © 2016 young-foxes.com. All Rights Reserved.
This page is made with Joomla CMS and its various templates designed by Fas Kuiters with the excellent Themler tool.

 

 

Shared Spreadsheet Links

DOV´s Revised Projections for the Periods 2017 until 2020

Shareble link : HERE

Fas Kuiters Websites